Therefore, the retina in early DR may release VEGF as a prosurvival factor, and a neuroprotective agent such as octreotide may decrease the need of VEGF production by the retina, therefore limiting the vasculopathy associated with VEGF upregulation. This evidence concerns the gene VEGFA and vascular disorder.